

Utilization of allogeneic hematopoietic stem cell transplantation among patients with newly diagnosed acute myeloid leukemia in California: a population-based linked dataset study

Christa L. Meyer,¹ Theresa H.M. Keegan,² Ann Brunson,² Jeffery J. Auletta,^{1,3} Lindsay M. Morton,⁴ Ted Wun,² Sara J. Schonfeld,⁴ Bryan Valcarcel,⁴ Renata Abrahão,² Rafeek A. Yusuf¹ and Lori Muffly⁵

¹Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN;

²Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA;

³Divisions of Hematology / Oncology / BMT and Infectious Diseases, Nationwide Children's Hospital, Columbus, OH; ⁴Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD and ⁵Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA

Correspondence: C. Meyer
cmeyer@nmdp.org

Received: April 26, 2024.

Accepted: August 19, 2024.

Early view: August 29, 2024.

<https://doi.org/10.3324/haematol.2024.285648>

©2025 Ferrata Storti Foundation


Published under a CC BY-NC license



Supplemental Table 1. Selection criteria table

Selection Criteria	Excluded	Included
CCR Dataset		N =373,381
Acute myelogenous leukemia (AML) diagnosed between 2001-2016	N =351,908	N =21,473
Include where AML is the only, or first, neoplasm reported to CCR	N =5,966	N =15,507
Include where AML is the only, or first, neoplasm reported to CIBMTR	N =118	N =15,389
Exclude Histology Type ICD-O-3: 9898-Myeloid leukemia associated with Down Syndrome (n=27), 9920-Therapy-related myeloid neoplasms (n=23), 9930-Myeloid sarcoma (n=145), 9931-Acute panmyelosis with myelofibrosis (n=92), 9987-Therapy-related myelodysplastic syndrome, NOS (n=31)	N =318	N =15,071
Exclude cases where survival was not calculated due to diagnosis being reported on a death certificate or autopsy only	N =156	N =14,915
Exclude if socioeconomic status (SES) is missing	N =417	N =14,498
Exclude if patient sex is not male or female (n=<5) or distance to center is not able to be calculated (n=<40)	N =32	N =14,466
Exclude if missing diagnosis date (n=206), missing HCT date (n=7), date of transplant is prior to date of diagnosis (n=7), date of last follow is prior to diagnosis date in CCR (n=16)	N =140	N =14,326
Exclude if age <15 (n=863) or >80 (n=2,863)	N =3,726	N =10600
Exclude if patient did not receive induction therapy	N =2,264	N =8,336
Exclude if transplant type is autologous (n=402) or unknown (n=9)	N =411	N =7,925

CCR=California Cancer Registry, CIBMTR=Center for International Blood and Marrow Transplant Research, ICD-O-3=International Classification of Diseases for Oncology (3rd Edition), HCT= Hematopoietic Cell Transplantation, NOS=Not otherwise specified



Supplemental Figure 1. Sensitivity Analysis: Cumulative Incidence of Allogeneic Hematopoietic Cell Transplant Utilization Among Newly Diagnosed Acute Myeloid Leukemia Patients in California, by Diagnosis Era. The cumulative incidence of allogeneic hematopoietic stem cell transplant was calculated accounting for the competing risk of death for each age group: Age 15-59 (A), Age 60-69 (B), Age 70-79 (C). The models were stratified by year of diagnosis grouped into 3 separate time periods (2001-2005, 2006-2010, 2011-2016). Time was calculated from month of Acute Myeloid Leukemia diagnosis.